Back to top

MS treatments on July PBAC agenda

5 May 2020
The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Australian Government about the medicines for subsidy through the Pharmaceutical Benefits Scheme (PBS).
Two treatments for MS will be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) at its July 2020 meeting:
1. Siponimod (Mayzent®) for the relapsing forms of MS.  Consideration of this treatment was held over from the March 2020 meeting of PBAC.  Siponimod was originally submitted to PBAC in late 2019 but it was not recommended for listing at that time (for more details, please refer to the MSA news item of 20 December 2019).  Since then the sponsor (Novartis) has provided additional material and has made a re-submission.
The PBAC Secretariat has confirmed that any consumer comments that were submitted between 24 December 2019 and 12 February 2020 for siponimod will be held over for consideration at the July meeting – no need to re-submit.
2. Ocrelizumab (Ocrevus®) for primary progressive MS (PPMS).  Ocrelizumab was recommended and approved for listing on the PBS for relapsing remitting MS in early 2018, but not for PPMS.  Since that time the sponsor (Roche) has gathered more evidence and tailored the re-submission to focus on people newly diagnosed with PPMS (based on clinician feedback) as this is where it seems to have the greatest impact in people with PPMS.
Consumer comments are now invited by PBAC and can be submitted until 10 June 2020.  Please visit: